GlassScriptPhysician profile
Albert A Crimaldi
NPI 1538262100
$5,102.18
in general payments reported to CMS, 2019-2025
20 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $251 · 2021: $485 · 2022: $958 · 2023: $896 · 2024: $1,020 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,129.06 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Phathom Pharmaceuticals, INC. | $369.73 | 2024-2025 | Voquezna |
| Pfizer INC. | $295.59 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.46 | 2019-2024 | Xifaxan |
| Madrigal Pharmaceuticals | $185.51 | 2024 | Rezdiffra, Resmetirom |
| Allergan, INC. | $182.25 | 2019 | |
| Celgene Corporation | $134.29 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $115.62 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $77.48 | 2022 | |
| Celltrion USA INC. | $74.99 | 2025 | Vegzelma |
| Fujifilm Healthcare Americas Corporation | $64.58 | 2023 | Fujifilm |
| Braintree Laboratories, INC. | $53.90 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $39.51 | 2021-2022 | |
| Pentax of America, INC. | $33.86 | 2020 | |
| Janssen Biotech, INC. | $32.54 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $27.75 | 2025 | |
| Ironwood Pharmaceuticals, INC | $20.51 | 2019 | |
| Intercept Pharmaceuticals, INC. | $18.15 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.04 | 2025 | Sutab |
| Olympus America INC. | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Crimaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.